| Charles W Sanderlin Jr, MD | |
|
3527 N Valdosta Rd, Valdosta, GA 31602-1068 | |
| (229) 247-2290 | |
| (229) 244-2626 |
| Full Name | Charles W Sanderlin Jr |
|---|---|
| Gender | Male |
| Speciality | Orthopedic Surgery |
| Experience | 27 Years |
| Location | 3527 N Valdosta Rd, Valdosta, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083618052 | NPI | - | NPPES |
| 265002900 | Medicaid | FL | |
| GRP1215 | Other | GA | MEDICARE PTAN |
| 00954445A | Medicaid | GA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207X00000X | Orthopaedic Surgery | 051543 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| South Georgia Medical Center | Valdosta, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Valdosta Orthopedic Associates Pc | 8325938491 | 20 |
News Archive
In a comparison of anticoagulants and stents for use with angioplasty following a heart attack, the anticoagulants abciximab and tirofiban had similar outcomes for some cardiac measures within 90 minutes after the procedure, while patients who received stents that released the drug sirolimus had a lower risk of major adverse cardiac events within 8 months than patients who received uncoated stents, according to a JAMA study being released early online March 30 to coincide with its presentation at the annual conference of the American College of Cardiology.
By introducing a particular strain of bacteria into the digestive tracts of mice with melanoma, researchers at the University of Chicago were able to boost the ability of the animal's immune systems to attack tumor cells. T
The National Institutes of Health (NIH) has awarded a consortium of Chicago-based institutions, led by Rush University Medical Center, a five-year, $3.75-million grant to establish a Developmental Center for AIDS Research, creating a comprehensive research infrastructure to spur basic science, clinical studies and translational research in the prevention, detection and treatment of HIV infection and AIDS.
Medivir AB today announces that the U.S. Food and Drug Administration has granted Priority Review to the New Drug Application by Janssen for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease.
› Verified 9 days ago
| Entity Name | Valdosta Orthopedic Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053457457 PECOS PAC ID: 8325938491 Enrollment ID: O20040319001326 |
News Archive
In a comparison of anticoagulants and stents for use with angioplasty following a heart attack, the anticoagulants abciximab and tirofiban had similar outcomes for some cardiac measures within 90 minutes after the procedure, while patients who received stents that released the drug sirolimus had a lower risk of major adverse cardiac events within 8 months than patients who received uncoated stents, according to a JAMA study being released early online March 30 to coincide with its presentation at the annual conference of the American College of Cardiology.
By introducing a particular strain of bacteria into the digestive tracts of mice with melanoma, researchers at the University of Chicago were able to boost the ability of the animal's immune systems to attack tumor cells. T
The National Institutes of Health (NIH) has awarded a consortium of Chicago-based institutions, led by Rush University Medical Center, a five-year, $3.75-million grant to establish a Developmental Center for AIDS Research, creating a comprehensive research infrastructure to spur basic science, clinical studies and translational research in the prevention, detection and treatment of HIV infection and AIDS.
Medivir AB today announces that the U.S. Food and Drug Administration has granted Priority Review to the New Drug Application by Janssen for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Charles W Sanderlin Jr, MD 3527 N Valdosta Rd, Valdosta, GA 31602-1068 Ph: (229) 247-2290 | Charles W Sanderlin Jr, MD 3527 N Valdosta Rd, Valdosta, GA 31602-1068 Ph: (229) 247-2290 |
News Archive
In a comparison of anticoagulants and stents for use with angioplasty following a heart attack, the anticoagulants abciximab and tirofiban had similar outcomes for some cardiac measures within 90 minutes after the procedure, while patients who received stents that released the drug sirolimus had a lower risk of major adverse cardiac events within 8 months than patients who received uncoated stents, according to a JAMA study being released early online March 30 to coincide with its presentation at the annual conference of the American College of Cardiology.
By introducing a particular strain of bacteria into the digestive tracts of mice with melanoma, researchers at the University of Chicago were able to boost the ability of the animal's immune systems to attack tumor cells. T
The National Institutes of Health (NIH) has awarded a consortium of Chicago-based institutions, led by Rush University Medical Center, a five-year, $3.75-million grant to establish a Developmental Center for AIDS Research, creating a comprehensive research infrastructure to spur basic science, clinical studies and translational research in the prevention, detection and treatment of HIV infection and AIDS.
Medivir AB today announces that the U.S. Food and Drug Administration has granted Priority Review to the New Drug Application by Janssen for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease.
› Verified 9 days ago
Eric C. Stiefel, M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3527 N Valdosta Rd, Valdosta, GA 31602 Phone: 229-247-2290 Fax: 229-247-5926 | |
Dr. Paul Dolphous Lane Jr., M.D. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3527 N Valdosta Rd, Valdosta, GA 31602 Phone: 229-247-2290 Fax: 229-247-0091 | |
James R. Goss, D.O. Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3527 N Valdosta Rd, Valdosta, GA 31602 Phone: 229-247-2290 Fax: 229-244-2626 | |
John P Kendrick, MD Orthopedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 3527 N Valdosta Rd, Valdosta, GA 31602 Phone: 229-247-2290 Fax: 229-244-2626 | |
Dr. Raymond Derry Crosby, DO Orthopedic Surgery Medicare: Medicare Enrolled Practice Location: 2310 N Patterson St, Bldg D, Valdosta, GA 31602 Phone: 229-247-2482 Fax: 229-247-0827 | |
William Louis Bacon, MD Orthopedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 206 E Adair St, Valdosta, GA 31601 Phone: 229-269-4250 Fax: 229-269-4521 |